[et_pb_section fb_built=”1″ _builder_version=”4.4.8″][et_pb_row _builder_version=”4.4.8″][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_text _builder_version=”4.4.8″ text_text_color=”#0C71C3″ text_font_size=”24px” text_orientation=”center”]

NETWORK FOR THE EMPIRICAL STUDY OF TRIPS+ INTELLECTUAL PROPERTY, TRADE AGREEMENTS, AND ACCESS TO HEALTH PRODUCTS

[/et_pb_text][et_pb_blurb _builder_version=”4.4.8″ custom_padding=”||5px|||”]

 

An informal network formed at the Global Congress on Intellectual Property and the Public Interest in 2018 to advance the empirical study of the impact of TRIPS-Plus Free Trade Agreements (and FTA provisions) on access to pharmaceuticals, vaccines, and diagnostics. We run a series of occasional webinars and an email list. To join the email list, visit tinyurl.com/fme-subscribe

[/et_pb_blurb][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.4.8″][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_divider _builder_version=”4.4.8″][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.4.8″][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_button button_text=”Webinars” button_alignment=”center” _builder_version=”4.4.8″][/et_pb_button][/et_pb_column][/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.4.8″ custom_padding=”|0px||0px|false|false”][et_pb_column type=”1_2″ _builder_version=”4.4.8″][et_pb_blurb title=”Presentation of the TRIPS-Plus PTA Dataset by Jean-Frédéric Morin” image=”http://infojustice.org/wp-content/uploads/2020/11/WTO-Trade-Agreement-Map-16×9-1.png” alt=”Map of FTAs” _builder_version=”4.7.3″ custom_padding=”|6px|||false|false”]

[November 15, 2020] The T + PTA dataset fills this gap by documenting the existence of 90 types of IP provisions in 126 agreements signed between 1991 and 2016. The dataset reveals that, even for like-minded countries, significant variations exist in their reliance on TRIPs-plus provisions, their degree of consistency across trade agreements, and their preferences for some IP rights. Flyer | Video

[/et_pb_blurb][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.4.8″][et_pb_blurb title=”PRESENTATION OF THE MEDSPAL DATABASE BY AMINA MAILLARD, MEDICINES PATENT POOL” image=”http://infojustice.org/wp-content/uploads/2020/09/mpp_logo_16x9.jpg” _builder_version=”4.7.3″ custom_margin=”|1px|||false|false” custom_padding=”||0px|6px|false|false”]

[September 15, 2020] MedsPaL is the Medicines Patent Pool (MPP)’s patents and licenses database, a free resource provides information on the intellectual property status of selected patent essential medicines in low- and middle-income countries (LMICs).
Flyer | Video

[/et_pb_blurb][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.4.8″][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_divider _builder_version=”4.4.8″][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.4.8″][et_pb_column type=”1_2″ _builder_version=”4.4.8″][et_pb_blurb title=”THE GLOBAL HEALTH IMPACT – Presentation by Professor Nicole Hassoun” image=”http://infojustice.org/wp-content/uploads/2020/09/ghi_pie_chart_16x9.png” _builder_version=”4.4.8″ custom_margin=”|1px||1px|false|false” custom_padding=”|4px||4px|false|false”]

[July 15, 2020] In Global Health Impact – Extending Access to Essential Medicines, Professor Nicole Hassoun proposes a novel approach to evaluate the impact of pharmaceuticals and pharmaceutical companies.
Flyer | Video

[/et_pb_blurb][/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.4.8″][et_pb_blurb title=”PANEL DISCUSSION ON the U.S.-MExico-Canada Agreement (NAFTA 2.0) AND ACCESS TO MEDICINES” image=”http://infojustice.org/wp-content/uploads/2020/09/usmca_webinar_image_16x9.png” _builder_version=”4.4.8″ custom_margin=”|||1px|false|false” custom_padding=”|2px||8px|false|false”]

[May 20, 2019] Burcu Kilic (Public Citizen), Joel Lexchin (York University) and Deborah Gleeson (La Trobe University) discuss how the recently-concluded United States-Mexico-Canada Agreement (USMCA) will impact access to affordable medicines.
Flyer | Video

[/et_pb_blurb][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.4.8″][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_divider _builder_version=”4.4.8″][/et_pb_divider][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”4.4.8″][et_pb_column type=”4_4″ _builder_version=”4.4.8″][et_pb_text _builder_version=”4.4.8″]

 

Studies of the Impact of FTAs with TRIPS+ Provisions

  • Danielle Trachtenberg, Warren A. Kaplan, Veronika J. Wirtz, and Kevin P. Gallagher. The Effects of Trade Agreements on Imports of Biologics: Evidence from Chile. Journal of Globalization and Development. Vol 10, No 2. (2020). Link.
  • Boston Univeristy Working Group on Trade, Investment Treaties & Access to Medicines. (Lead Authors: Rachel D. Thrasher, Veronika J. Wirtz, Warren Kaplan, Kevin P. Gallagher, Hattie Werk). Rethinking Trade Treaties and Access to Medicines. (2019). Link.
  • Ellen R. Shaffer and Joseph E. Brenner. A Trade Agreement’s Impact On Access To Generic Drugs. Journal of Health Affairs. (2009) Link.
  • Rohit Malpani. All Costs, No Benefits: How the US-Jordan Free Trade Agreement Affects Access to Medicines. Journal of Generic Medicines. Vol 6, No. 3. (2009). Link. 

Studies of the Impact of TRIPS+ Provisions Frequently Found in FTAs

Studies on the impact of secondary patents

  • María José Abud, Bronwyn Hall, and Christian Helmers. An Empirical Analysis of Primary and Secondary Pharmaceutical Patents in Chile. PLoS ONE. (2015) Link.
  • Amy Kapczynski, Chan Park, and Bhaven Sampat. Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents. PLoS ONE. (2015). Link. 
  • I-MAK. Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices. White paper. (2015). Link.

Studies on the impact of data exclusivity

  • Michael Palmedo.  Evaluating the Impact of Data Exclusivity on the Price per Kilogram of Pharmaceutical Imports. GEGI Working Paper no. 48. Boston University Global Development Policy Center. (April 2021). Link.
  • Miguel Ernesto Cortés Gamba, Francisco Rossi Buenaventura, and Mayra Damaris Vásquez Serrano. Impacto de 10 Años de Protección de Datos en Medicamentos en Colombia. Serie Buscando Remedio No. 2. (2013). Link
  • Aaron S. Kesselheim and Daniel H. Solomon. Incentives for Drug Development — The Curious Case of Colchicine. New England Journal of Medicine. (2010). Link. 

Studies on the impact of Linkage

  • Ron A. Bouchard, Richard W. Hawkins, Robert Clark, Reider Hagtvedt, and Jamil Sawani. Empirical Analysis of Drug Approval-Drug Patenting Linkage for High Value Pharmaceuticals. Northwestern Journal of Technology and Intellectual Property. Vol. 8 No. 2. (2010). Link.

Studies on the impact of TRIPS+ enforcement

  • John Zarocostas. Brazil and India file complaint against EU over seizure of generic drugs. British Medical Journal, 340. (2010). Link. 

 

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]